228 related articles for article (PubMed ID: 25667369)
1. The emerging role of denosumab in the long-term management of parathyroid carcinoma-related refractory hypercalcemia.
Fountas A; Andrikoula M; Giotaki Z; Limniati C; Tsakiridou E; Tigas S; Tsatsoulis A
Endocr Pract; 2015 May; 21(5):468-73. PubMed ID: 25667369
[TBL] [Abstract][Full Text] [Related]
2. Control of Refractory Hypercalcemia with Denosumab in a Case of Metastatic Parathyroid Carcinoma.
Çalapkulu M; Gul OO; Cander S; Ersoy C; Erturk E; Sagiroglu MF; Saraydaroglu O
J Coll Physicians Surg Pak; 2020 Jul; 30(7):757-759. PubMed ID: 32811610
[TBL] [Abstract][Full Text] [Related]
3. Denosumab for the Treatment of Hypercalcemia in a Patient With Parathyroid Carcinoma: A Case Report.
Roukain A; Alwan H; Bongiovanni M; Sykiotis GP; Kopp PA
Front Endocrinol (Lausanne); 2021; 12():794988. PubMed ID: 35173680
[TBL] [Abstract][Full Text] [Related]
4. Denosumab for management of parathyroid carcinoma-mediated hypercalcemia.
Vellanki P; Lange K; Elaraj D; Kopp PA; El Muayed M
J Clin Endocrinol Metab; 2014 Feb; 99(2):387-90. PubMed ID: 24178790
[TBL] [Abstract][Full Text] [Related]
5. Successful Control of Hypercalcemia with Sorafenib, Evocalcet, and Denosumab Combination Therapy for Recurrent Parathyroid Carcinoma.
Makino H; Notsu M; Asayama I; Otani H; Morita M; Yamamoto M; Yamauchi M; Nakao M; Miyake H; Araki A; Uchino S; Kanasaki K
Intern Med; 2022 Nov; 61(22):3383-3390. PubMed ID: 35370235
[TBL] [Abstract][Full Text] [Related]
6. Effective long-term management of parathyromatosis-related refractory hypercalcemia with a combination of denosumab and cinacalcet treatment.
Tzotzas T; Goropoulos A; Karras S; Terzaki A; Siolos A; Doumas A; Zaramboukas T; Tigas S
Hormones (Athens); 2022 Mar; 21(1):171-176. PubMed ID: 34993886
[TBL] [Abstract][Full Text] [Related]
7. Ectopic parathyroid hormone as a rare aetiology of hypercalcemia with rhabdomyosarcoma: a new treatment strategy with zoledronic acid and Denosumab.
Kilci F; Demirsoy U; Jones JH; Çakır Ö; Çizmecioğlu-Jones FM
J Pediatr Endocrinol Metab; 2022 Aug; 35(8):1107-1112. PubMed ID: 35534911
[TBL] [Abstract][Full Text] [Related]
8. Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab.
Uchida T; Yamaguchi H; Kushima C; Yonekawa T; Nakazato M
Endocr J; 2020 Jan; 67(1):31-35. PubMed ID: 31527321
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent.
Collins MT; Skarulis MC; Bilezikian JP; Silverberg SJ; Spiegel AM; Marx SJ
J Clin Endocrinol Metab; 1998 Apr; 83(4):1083-8. PubMed ID: 9543122
[TBL] [Abstract][Full Text] [Related]
10. Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab.
Karuppiah D; Thanabalasingham G; Shine B; Wang LM; Sadler GP; Karavitaki N; Grossman AB
Eur J Endocrinol; 2014 Jul; 171(1):K1-5. PubMed ID: 24743399
[TBL] [Abstract][Full Text] [Related]
11. Denosumab is Effective for Controlling Serum Calcium Levels in Patients with Humoral Hypercalcemia of Malignancy Syndrome: A Case Report on Parathyroid Hormone-related Protein-producing Cholangiocarcinoma.
Ashihara N; Nakajima K; Nakamura Y; Kobayashi M; Shirahata K; Maeda C; Uehara T; Gomi D; Ito N
Intern Med; 2016; 55(23):3453-3457. PubMed ID: 27904108
[TBL] [Abstract][Full Text] [Related]
12. First Japanese patient treated with parathyroid hormone peptide immunization for refractory hypercalcemia caused by metastatic parathyroid carcinoma.
Horie I; Ando T; Inokuchi N; Mihara Y; Miura S; Imaizumi M; Usa T; Kinoshita N; Sekine I; Kamihara S; Eguchi K
Endocr J; 2010; 57(4):287-92. PubMed ID: 20051648
[TBL] [Abstract][Full Text] [Related]
13. Denosumab treatment for refractory hypercalcemia in a hemodialysis patient with tertiary hyperparathyroidism.
Zhang P; Yu Y; Gao Y; Yuan G; Zhang J; Wang W
Hemodial Int; 2023 Apr; 27(2):E23-E28. PubMed ID: 36719850
[TBL] [Abstract][Full Text] [Related]
14. A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on the Treatment of Hypercalcemia of Malignancy in Adults.
Seisa MO; Nayfeh T; Hasan B; Firwana M; Saadi S; Mushannen A; Shah SH; Rajjoub NS; Farah MH; Prokop LJ; Wang Z; Fuleihan GE; Drake MT; Murad MH
J Clin Endocrinol Metab; 2023 Feb; 108(3):585-591. PubMed ID: 36545700
[TBL] [Abstract][Full Text] [Related]
15. [Effect of cinacalcet on parathyroid hormone level in hypercalcemic hyperparathyroidism of patients with renal transplantation].
Vaquero E; Esteban de la Rosa RJ; Oliva N; Fernández Castillo R; Fernández Gallegos R; Bravo Soto J
Med Clin (Barc); 2012 Apr; 138(8):323-6. PubMed ID: 21492884
[TBL] [Abstract][Full Text] [Related]
16. Use of denosumab in parathyroid carcinoma with refractory hypercalcemia.
Tong CV; Hussein Z; Noor NM; Mohamad M; Ng WF
QJM; 2015 Jan; 108(1):49-50. PubMed ID: 25099611
[No Abstract] [Full Text] [Related]
17. Gallium nitrate for treatment of refractory hypercalcemia from parathyroid carcinoma.
Warrell RP; Issacs M; Alcock NW; Bockman RS
Ann Intern Med; 1987 Nov; 107(5):683-6. PubMed ID: 2821862
[TBL] [Abstract][Full Text] [Related]
18. Palliative treatment of uncontrollable hypercalcemia due to parathyrotoxicosis: denosumab as rescue therapy.
Jumpertz von Schwartzenberg R; Elbelt U; Ventz M; Mai K; Kienitz T; Maurer L; Rose T; Rückert JC; Strasburger CJ; Spranger J
Endocrinol Diabetes Metab Case Rep; 2015; 2015():150082. PubMed ID: 26605043
[TBL] [Abstract][Full Text] [Related]
19. Use of denosumab to treat refractory hypercalcemia in a peritoneal dialysis patient with immobilization and tertiary hyperparathyroidism.
Pratt RM; West ML; Tennankore KK
Perit Dial Int; 2020 Jan; 40(1):103-106. PubMed ID: 32063140
[TBL] [Abstract][Full Text] [Related]
20. Hypercalcemia secondary to persistent hyperparathyroidism in kidney transplant patients: analysis after a year with cinacalcet.
Guerra R; Auyanet I; Fernández EJ; Pérez MÁ; Bosch E; Ramírez A; Suria S; Checa MD
J Nephrol; 2011; 24(1):78-82. PubMed ID: 20437396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
